MET and non-small cell lung carcinoma: Overall, the highest ORR was observed among patients with c-Met protein-overexpressing, non-squamous EGFR-wild-type NSCLC (37%), and ORR was improved in high-c-Met cases (52%), although PFS and overall survival (OS) were comparable regardless of the level of c-Met expression [95].